Clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2039-2042

  Leroux, Stéphanie ^a,b,c   Jacqz Aigrain, Evelyne ^a,b,d   Biran, Valérie ^a   Lopez, Emmanuel ^e   Madeleneau, Doriane ^f   Wallon, Camille ^e   Zana Taïeb, Elodie ^f   Virlouvet, Anne Laure ^a   Rioualen, Stéphane ^a   Zhao, Wei ^g  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e Centre de Pediatrie Clocheville   (France)

^f université Paris Cité   (France)

^g SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; DRUG UTILIZATION; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEWBORN; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; DRUG ADMINISTRATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; INFANT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; NEONATAL INTENSIVE CARE UNIT; PATIENT SAFETY; PERSONALIZED MEDICINE; STAPHYLOCOCCAL INFECTIONS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, STATISTICAL; PATIENT SAFETY; PRECISION MEDICINE; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84963650320     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02214-15     Document Type: Article

References (17)

1. Schlapbach LJ, Mattmann M, Thiel S, Boillat C, Otth M, Nelle M, Wagner B, Jensenius JC, Aebi C. 2010. Differential role of the lectin pathway of complement activation in susceptibility to neonatal sepsis. Clin Infect Dis 51:153-162. http://dx.doi.org/10.1086/653531.
2. Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B, Israel Neonatal Network. 2005. Pathogen-specific early mortality in very low birth weight infants with late-onset sepsis: A national survey. Clin Infect Dis 40:218- 224. http://dx.doi.org/10.1086/426444.
3. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. 2013. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 18:28-34. http://dx.doi.org/10.1016/j.siny.2012.10.003.
4. deHoog M, Mouton JW, vandenAnker JN. 2004. Vancomycin: Pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 43: 417-440. http://dx.doi.org/10.2165/00003088-200443070-00001.
5. Marsot A, Boulamery A, Bruguerolle B, Simon N. 2012. Population pharmacokinetic analysis during the first 2 years of life: An overview. Clin Pharmacokinet 51:787-798. http://dx.doi.org/10.1007/s40262-012-0015-8.
6. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. 2013. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child 98:449-453. http://dx.doi.org/10.1136/archdischild-2012-302765.
7. Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T. 1999. Lack of vancomycin-associated nephrotoxicity in newborn infants: A case-control study. Pediatrics 103:e48. http://dx.doi.org/10.1542/peds.103.4.e48.
8. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167. http://dx.doi.org/10.1056/NEJMra035092.
9. Zhao W, Leroux S, Jacqz-Aigrain E. 2014. Dosage individualization in children: integration of pharmacometrics in clinical practice. World J Pediatr 10:197-203. http://dx.doi.org/10.1007/s12519-014-0493-x.
10. Wang J, Avant D, Green D, Seo S, Fisher J, Mulberg AE, McCune SK, Burckart GJ. 2015. A survey of neonatal pharmacokinetic and pharmacodynamic studies in pediatric drug development. Clin Pharmacol Ther 98:328-335. http://dx.doi.org/10.1002/cpt.149.
11. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925-942. http://dx.doi.org/10.2165/00003088-200443130-00005.
12. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. 2010. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 123:1143-1149. http://dx.doi.org/10.1016/j.amjmed.2010.07.025.
13. Smits A, Annaert P, Allegaert K. 2013. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int J Pharm 452:8 -13. http://dx.doi.org/10.1016/j.ijpharm.2012.03.035.
14. Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. 2010. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother 54:2626-2632. http://dx.doi.org/10.1128/AAC.01370-09.
15. deHoog M, Schoemaker RC, Mouton JW, van den Anker JN. 2000. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther 67:360-367. http://dx.doi.org/10.1067/mcp.2000.105353.
16. Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. 2015. How to use vancomycin optimally in neonates: Remaining questions. Expert Rev Clin Pharmacol 8:635-648. http://dx.doi.org/10.1586/17512433.2015.1060124.
17. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. 2012. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68: 1243-1255. http://dx.doi.org/10.1007/s00228-012-1259-9.